Glück Conviction Score™ ⓘ
DGX
QUEST DIAGNOSTICS INC
ⓘ
Eingeschränkte Aussagekraft — erst 61 % der Signal-Gewichte sind mit Daten unterlegt.
Effektiv: Stark
Hoch
Bedeutung der Einstufung ⓘ
Insider
0,0
Keine Insider-Käufe
Institutionell
71,2
118 neu, 348 erhöht, -22510K $ netto
Aktivist
46,8
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,69% (Stand: 31.05.2026)
Score-Verlauf (90 Tage)
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (12 Monate)
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 194.80 | +4.2 % vs SMA50 | |
| Kurs vs SMA200 | Bullisch | 15 % | 189.20 | +7.3 % vs SMA200 | |
| EMA20 vs EMA50 | Bullisch | 5 % | 197.39 | EMA50: 195.60 | |
| MACD-Histogramm | Bullisch | 10 % | 1.195 | Bullisch | |
| RSI(14) | Neutral | 10 % | 62.1 | Neutral (30–70) | |
| Stoch %K(14) | Neutral | 5 % | 73.1 | Neutral | |
| ADX(14)+DI | Neutral | 10 % | 20.7 | +DI: 24.9 / −DI: 11.3 | |
| Z-Score(60) | Bärisch | 5 % | 1.87 | Extrem überkauft | |
| 52W-Position | Bullisch | 5 % | 80.5 % | Hoch 211.91 / Tief 166.42 | |
| Bollinger(20,2σ) | Bärisch | 5 % | 87.4 % | Upper 205.51 / Mid 195.77 / Lower 186.03 | |
| LinReg-Slope(60) | Neutral | 10 % | -0.0013 | R²=0.00 / annualisiert -0.2 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-06-04 | KUPPUSAMY KARTHIK | Officer, SVP, Clinical Solutions | Open Market Sale | -8.147 | 200,00 | -1.629.400,00 | -227,4% | |
| 2026-06-01 | Davis J. E. | Director, Officer, CEO and President | Open Market Sale | -10.000 | 194,14 | -1.941.400,00 | -270,9% | |
| 2026-04-20 | CARTER ROBERT B | Director | Small Acquisition | 7 | 194,70 | 1.362,89 | +0,2% | |
| 2026-04-20 | Plewman Patrick | Officer, SVP for Diagnostic Services | Small Acquisition | 49 | 194,70 | 9.540,25 | +1,3% | |
| 2026-04-20 | Lassiter Wright III | Director | Small Acquisition | 6 | 194,70 | 1.168,19 | +0,2% | |
| 2026-04-20 | KUPPUSAMY KARTHIK | Officer, SVP, Clinical Solutions | Small Acquisition | 39 | 194,70 | 7.593,26 | +1,1% | |
| 2026-04-20 | DELANEY MARK E | Officer, SVP & Chief Commercial Officer | Small Acquisition | 37 | 194,70 | 7.203,75 | +1,0% | |
| 2026-03-05 | PREVOZNIK MICHAEL E | Officer, SVP & General Counsel | Open Market Sale | -3.878 | 206,21 | -799.682,38 | -111,6% | |
| 2026-03-05 | Doherty Catherine T. | Officer, EVP, Regional Businesses | Open Market Sale | -5.558 | 206,21 | -1.146.115,18 | -160,0% | |
| 2026-03-05 | Plewman Patrick | Officer, SVP for Diagnostic Services | Open Market Sale | -2.855 | 206,21 | -588.729,55 | -82,2% | |
| 2026-03-04 | KUPPUSAMY KARTHIK | Officer, SVP, Clinical Solutions | Open Market Sale | -2.628 | 204,86 | -538.372,08 | -75,1% | |
| 2026-03-03 | PREVOZNIK MICHAEL E | Officer, SVP & General Counsel | Open Market Sale | -526 | 207,73 | -109.265,98 | -15,2% | |
| 2026-03-03 | Plewman Patrick | Officer, SVP for Diagnostic Services | Open Market Sale | -410 | 207,73 | -85.169,30 | -11,9% | |
| 2026-03-03 | Doherty Catherine T. | Officer, EVP, Regional Businesses | Open Market Sale | -632 | 207,73 | -131.285,36 | -18,3% | |
| 2026-03-02 | Davis J. E. | Director, Officer, CEO and President | Open Market Sale | -10.000 | 212,52 | -2.125.200,00 | -296,6% | |
| 2026-02-19 | Doherty Catherine T. | Officer, EVP, Regional Businesses | Open Market Sale | -1.433 | 204,83 | -293.521,39 | -41,0% | |
| 2026-02-19 | Plewman Patrick | Officer, SVP for Diagnostic Services | Open Market Sale | -958 | 204,83 | -196.227,14 | -27,4% | |
| 2026-02-19 | PREVOZNIK MICHAEL E | Officer, SVP & General Counsel | Open Market Sale | -1.111 | 204,83 | -227.566,13 | -31,8% | |
| 2026-02-13 | Doherty Catherine T. | Officer, EVP, Regional Businesses | Open Market Sale | -351 | 209,10 | -73.394,94 | -10,2% | |
| 2026-02-13 | Doherty Catherine T. | Officer, EVP, Regional Businesses | Open Market Sale | -10.573 | 205,21 | -2.169.655,73 | -302,8% | |
| 2026-02-13 | Doherty Catherine T. | Officer, EVP, Regional Businesses | Open Market Sale | -10.122 | 206,37 | -2.088.883,21 | -291,5% | |
| 2026-02-13 | Doherty Catherine T. | Officer, EVP, Regional Businesses | Open Market Sale | -3.500 | 207,08 | -724.787,70 | -101,2% | |
| 2026-02-13 | Doherty Catherine T. | Officer, EVP, Regional Businesses | Open Market Sale | -1.619 | 208,21 | -337.093,12 | -47,0% | |
| 2026-02-10 | Plewman Patrick | Officer, SVP for Diagnostic Services | Open Market Sale | -5.662 | 204,00 | -1.155.048,00 | -161,2% | |
| 2026-01-28 | Lassiter Wright III | Director | Small Acquisition | 7 | 183,51 | 1.284,57 | +0,2% | |
| 2026-01-28 | Gregg Vicky B | Director | Small Acquisition | 67 | 183,51 | 12.295,37 | +1,7% | |
| 2026-01-28 | CARTER ROBERT B | Director | Small Acquisition | 6 | 183,51 | 1.101,06 | +0,2% | |
| 2026-01-28 | KUPPUSAMY KARTHIK | Officer, SVP, Clinical Solutions | Small Acquisition | 16 | 183,52 | 2.936,26 | +0,4% | |
| 2026-01-28 | DELANEY MARK E | Officer, SVP & Chief Commercial Officer | Small Acquisition | 15 | 183,51 | 2.752,65 | +0,4% | |
| 2025-11-25 | Gregg Vicky B | Director | Open Market Sale | -1.250 | 191,76 | -239.700,00 | -33,5% | |
| 2025-11-25 | Davis J. E. | Director, Officer, CEO and President | Open Market Sale | -4.747 | 192,97 | -916.036,66 | -127,8% | |
| 2025-11-25 | Davis J. E. | Director, Officer, CEO and President | Open Market Sale | -9.342 | 191,59 | -1.789.822,57 | -249,8% | |
| 2025-11-25 | Davis J. E. | Director, Officer, CEO and President | Open Market Sale | -41.004 | 192,27 | -7.883.900,59 | -1100,3% | |
| 2025-11-18 | DELANEY MARK E | Officer, SVP & Chief Commercial Officer | Open Market Sale | -7.946 | 187,35 | -1.488.683,10 | -207,8% | |
| 2025-10-22 | PFEIFFER GARY M | Director | Open Market Sale | -1.482 | 182,40 | -270.316,80 | -37,7% | |
| 2025-09-26 | PREVOZNIK MICHAEL E | Officer, SVP & General Counsel | Open Market Sale | -144 | 188,66 | -27.166,77 | -3,8% | |
| 2025-09-26 | PREVOZNIK MICHAEL E | Officer, SVP & General Counsel | Open Market Sale | -83 | 187,22 | -15.539,24 | -2,2% | |
| 2025-09-24 | PREVOZNIK MICHAEL E | Officer, SVP & General Counsel | Open Market Sale | -175 | 187,02 | -32.729,03 | -4,6% | |
| 2025-09-23 | PREVOZNIK MICHAEL E | Officer, SVP & General Counsel | Open Market Sale | -28.288 | 187,12 | -5.293.312,79 | -738,7% | |
| 2025-08-21 | Plewman Patrick | Officer, SVP for Diagnostic Services | Open Market Sale | -1.975 | 185,00 | -365.375,00 | -51,0% | |
| 2025-08-19 | Plewman Patrick | Officer, SVP for Diagnostic Services | Open Market Sale | -4.532 | 183,00 | -829.356,00 | -115,7% | |
| 2025-08-15 | Plewman Patrick | Officer, SVP for Diagnostic Services | Open Market Sale | -1.975 | 180,00 | -355.500,00 | -49,6% | |
| 2025-08-06 | Plewman Patrick | Officer, SVP for Diagnostic Services | Open Market Sale | -1.975 | 175,00 | -345.625,00 | -48,2% | |
| 2025-08-06 | Plewman Patrick | Officer, SVP for Diagnostic Services | Open Market Sale | -3.560 | 175,00 | -623.000,00 | -86,9% | |
| 2025-07-31 | KUPPUSAMY KARTHIK | Officer, SVP, Clinical Solutions | Open Market Sale | -2.210 | 170,00 | -375.700,00 | -52,4% | |
| 2025-07-30 | KUPPUSAMY KARTHIK | Officer, SVP, Clinical Solutions | Open Market Sale | -5.224 | 167,40 | -874.497,60 | -122,0% | |
| 2025-07-30 | KUPPUSAMY KARTHIK | Officer, SVP, Clinical Solutions | Open Market Sale | -3.045 | 167,40 | -509.733,00 | -71,1% | |
| 2025-07-21 | Lassiter Wright III | Director | Small Acquisition | 7 | 167,51 | 1.172,54 | +0,2% | |
| 2025-07-21 | Gregg Vicky B | Director | Small Acquisition | 79 | 167,50 | 13.232,11 | +1,8% | |
| 2025-07-21 | SAMAD SAM | Officer, Executive Vice President & CFO | Small Acquisition | 72 | 167,50 | 12.059,71 | +1,7% | |
| 2025-07-21 | CARTER ROBERT B | Director | Small Acquisition | 7 | 167,51 | 1.172,54 | +0,2% | |
| 2025-07-21 | Plewman Patrick | Officer, SVP for Diagnostic Services | Small Acquisition | 80 | 167,49 | 13.399,52 | +1,9% | |
| 2025-07-21 | DELANEY MARK E | Officer, SVP & Chief Commercial Officer | Small Acquisition | 17 | 167,49 | 2.847,35 | +0,4% | |
| 2025-07-21 | KUPPUSAMY KARTHIK | Officer, SVP, Clinical Solutions | Small Acquisition | 27 | 167,50 | 4.522,45 | +0,6% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | 14.392.082 | 0 | 14.392.082 | 2.497.458.052 | Neu | +100,0% | |
| BlackRock, Inc. | 9.172.292 | 9.459.218 | -286.926 | 1.797.585.732 | Reduziert | -3,0% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 7.145.672 | 0 | 7.145.672 | 1.400.408.799 | Neu | +100,0% | |
| STATE STREET CORP | 5.380.821 | 5.382.547 | -1.726 | 1.054.533.300 | Reduziert | 0,0% | |
| Boston Partners | 4.012.232 | 3.913.326 | 98.906 | 786.652.146 | Aufgestockt | +2,5% | |
| JPMORGAN CHASE & CO | 4.145.896 | 0 | 4.145.896 | 719.437.502 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 3.086.308 | 3.028.207 | 58.101 | 602.658.595 | Aufgestockt | +1,9% | |
| MORGAN STANLEY | 2.479.720 | 2.693.568 | -213.848 | 485.976.070 | Reduziert | -7,9% | |
| EdgePoint Investment Group Inc. | 2.243.869 | 1.661.072 | 582.797 | 439.753.447 | Aufgestockt | +35,1% | |
| DIMENSIONAL FUND ADVISORS LP | 1.949.535 | 1.931.548 | 17.987 | 382.085.386 | Aufgestockt | +0,9% | |
| Grantham, Mayo, Van Otterloo & Co. LLC | 1.883.024 | 1.816.060 | 66.964 | 369.035.502 | Aufgestockt | +3,7% | |
| VICTORY CAPITAL MANAGEMENT INC | 1.846.336 | 2.126.422 | -280.086 | 361.844.958 | Reduziert | -13,2% | |
| WELLS FARGO & COMPANY/MN | 1.762.769 | 1.769.093 | -6.324 | 345.467.202 | Reduziert | -0,4% | |
| BANK OF AMERICA CORP /DE/ | 1.752.902 | 1.622.938 | 129.964 | 343.533.753 | Aufgestockt | +8,0% | |
| Invesco Ltd. | 1.638.487 | 1.666.979 | -28.492 | 321.110.683 | Reduziert | -1,7% | |
| DAVIS SELECTED ADVISERS | 1.617.813 | 1.589.883 | 27.930 | 317.062.477 | Aufgestockt | +1,8% | |
| GOLDMAN SACHS GROUP INC | 1.348.694 | 1.762.925 | -414.231 | 264.317.118 | Reduziert | -23,5% | |
| NORGES BANK | 1.322.663 | 0 | 1.322.663 | 229.521.710 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 1.114.219 | 1.078.573 | 35.646 | 218.364.640 | Aufgestockt | +3,3% | |
| FMR LLC | 942.218 | 1.202.254 | -260.036 | 184.655.952 | Reduziert | -21,6% | |
| AMERICAN CENTURY COMPANIES INC | 867.331 | 870.500 | -3.169 | 169.979.895 | Reduziert | -0,4% | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 846.603 | 846.935 | -332 | 165.917.256 | Reduziert | 0,0% | |
| AMERIPRISE FINANCIAL INC | 807.477 | 813.454 | -5.977 | 158.252.826 | Reduziert | -0,7% | |
| M&G Plc | 805.341 | 945.052 | -139.711 | 157.846.836 | Reduziert | -14,8% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 760.790 | 751.054 | 9.736 | 149.099.624 | Aufgestockt | +1,3% | |
| Legal & General Group Plc | 736.625 | 742.974 | -6.349 | 144.363.772 | Reduziert | -0,9% | |
| Qube Research & Technologies Ltd | 734.714 | 733.456 | 1.258 | 143.989.250 | Aufgestockt | +0,2% | |
| FIDUCIARY MANAGEMENT INC /WI/ | 720.986 | 1.046.921 | -325.935 | 141.298.836 | Reduziert | -31,1% | |
| UBS Group AG | 702.337 | 1.114.451 | -412.114 | 137.644.005 | Reduziert | -37,0% | |
| ALLIANCEBERNSTEIN L.P. | 681.158 | 632.407 | 48.751 | 118.201.348 | Aufgestockt | +7,7% | |
| Woodline Partners LP | 593.744 | 341.372 | 252.372 | 116.361.949 | Aufgestockt | +73,9% | |
| BARCLAYS PLC | 565.470 | 333.302 | 232.168 | 110.820.812 | Aufgestockt | +69,7% | |
| DEUTSCHE BANK AG\ | 550.899 | 609.081 | -58.182 | 107.965.187 | Reduziert | -9,6% | |
| PRINCIPAL FINANCIAL GROUP INC | 526.033 | 531.286 | -5.253 | 103.095.231 | Reduziert | -1,0% | |
| CITADEL ADVISORS LLC | 489.518 | 504.936 | -15.418 | 95.935.738 | Reduziert | -3,1% | |
| CRAWFORD INVESTMENT COUNSEL INC | 486.433 | 496.499 | -10.066 | 95.331.208 | Reduziert | -2,0% | |
| Nuveen, LLC | 465.425 | 334.034 | 131.391 | 91.213.992 | Aufgestockt | +39,3% | |
| RAYMOND JAMES FINANCIAL INC | 458.455 | 463.282 | -4.827 | 89.848.109 | Reduziert | -1,0% | |
| Artemis Investment Management LLP | 447.274 | 460.725 | -13.451 | 87.656.759 | Reduziert | -2,9% | |
| ENVESTNET ASSET MANAGEMENT INC | 412.436 | 333.803 | 78.633 | 80.829.155 | Aufgestockt | +23,6% | |
| Amundi | 408.330 | 464.164 | -55.834 | 80.024.513 | Reduziert | -12,0% | |
| Pacer Advisors, Inc. | 447.727 | 0 | 447.727 | 77.694.066 | Neu | +100,0% | |
| Squarepoint Ops LLC | 345.788 | 575.900 | -230.112 | 67.767.532 | Reduziert | -40,0% | |
| FIRST TRUST ADVISORS LP | 329.152 | 351.709 | -22.557 | 64.507.097 | Reduziert | -6,4% | |
| Advisors Capital Management, LLC | 327.251 | 313.838 | 13.413 | 64.134.663 | Aufgestockt | +4,3% | |
| Swiss National Bank | 326.500 | 306.500 | 20.000 | 63.987.470 | Aufgestockt | +6,5% | |
| M.D. Sass, LLC | 299.459 | 0 | 299.459 | 58.687.975 | Neu | +100,0% | |
| SCHRODER INVESTMENT MANAGEMENT GROUP | 295.035 | 257.380 | 37.655 | 58.169.101 | Aufgestockt | +14,6% | |
| CITIGROUP INC | 287.123 | 309.817 | -22.694 | 56.270.270 | Reduziert | -7,3% | |
| BNP PARIBAS FINANCIAL MARKETS | 270.281 | 228.057 | 42.224 | 52.969.670 | Aufgestockt | +18,5% |
Top-Fondshalter (Stand: 31.03.2026) ⓘ
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) |
|---|---|---|---|---|---|
| BlackRock, Inc. | 9.172.292 | 9.459.218 | -3,0% | 1.797.585.732 | 10,69 |
| VANGUARD CAPITAL MANAGEMENT LLC | 7.145.672 | 0 | +100,0% | 1.400.408.799 | 8,33 |
| STATE STREET CORP | 5.380.821 | 5.382.547 | 0,0% | 1.054.533.300 | 6,27 |
| Boston Partners | 4.012.232 | 3.913.326 | +2,5% | 786.652.146 | 4,68 |
| JPMORGAN CHASE & CO | 3.846.456 | 4.145.896 | -7,2% | 758.367.688 | 4,51 |
| GEODE CAPITAL MANAGEMENT, LLC | 3.086.308 | 3.028.207 | +1,9% | 602.658.595 | 3,58 |
| MORGAN STANLEY | 2.479.720 | 2.693.568 | -7,9% | 485.976.070 | 2,89 |
| EdgePoint Investment Group Inc. | 2.243.869 | 1.661.072 | +35,1% | 439.753.447 | 2,61 |
| DIMENSIONAL FUND ADVISORS LP | 1.949.535 | 1.931.548 | +0,9% | 382.085.386 | 2,27 |
| Grantham, Mayo, Van Otterloo & Co. LLC | 1.883.024 | 1.816.060 | +3,7% | 369.035.502 | 2,19 |
| VICTORY CAPITAL MANAGEMENT INC | 1.846.336 | 2.126.422 | -13,2% | 361.844.958 | 2,15 |
| WELLS FARGO & COMPANY/MN | 1.762.769 | 1.769.093 | -0,4% | 345.467.202 | 2,05 |
| BANK OF AMERICA CORP /DE/ | 1.752.902 | 1.622.938 | +8,0% | 343.533.753 | 2,04 |
| Invesco Ltd. | 1.638.487 | 1.666.979 | -1,7% | 321.110.683 | 1,91 |
| DAVIS SELECTED ADVISERS | 1.617.813 | 1.589.883 | +1,8% | 317.062.477 | 1,89 |
| GOLDMAN SACHS GROUP INC | 1.348.694 | 1.762.925 | -23,5% | 264.317.118 | 1,57 |
| NORTHERN TRUST CORP | 1.114.219 | 1.078.573 | +3,3% | 218.364.640 | 1,30 |
| FMR LLC | 942.218 | 1.202.254 | -21,6% | 184.655.952 | 1,10 |
| AMERICAN CENTURY COMPANIES INC | 867.331 | 870.500 | -0,4% | 169.979.895 | 1,01 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 846.603 | 846.935 | 0,0% | 165.917.256 | 0,99 |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 31.03.2026 | ✓ | 1.045 | 109,9 | 19.767 |
| 31.12.2025 | ✓ | 1.026 | 111,5 | 17.749 |
| 30.09.2025 | ✓ | 998 | 115,7 | 20.141 |
| 30.06.2025 | ✓ | 973 | 114,4 | 18.565 |
| 31.03.2025 | ✓ | 947 | 108,8 | 16.811 |
| 31.12.2024 | ✓ | 873 | 104,0 | 14.414 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) ⓘ |
|---|---|---|
| NORGES BANK | 1.322.663 | 229.521.710 |
| D. E. Shaw & Co., Inc. | 328.734 | 57.045.211 |
| Freestone Grove Partners LP | 309.214 | 53.657.905 |
| Eurizon Capital SGR S.p.A. | 249.182 | 43.243.664 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 246.054 | 42.698.000 |
| CONNING INC. | 173.262 | 30.066.156 |
| Point72 Asset Management, L.P. | 100.301 | 17.405.233 |
| CANADA PENSION PLAN INVESTMENT BOARD | 90.700 | 15.739.171 |
| Distillate Capital Partners LLC | 88.756 | 15.401.829 |
| GLENMEDE TRUST CO NA | 88.576 | 15.370.592 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| EdgePoint Investment Group Inc. | 1.661.072 | 811.320 | +95.5 % | 288.245.824 |
| GOLDMAN SACHS GROUP INC | 1.762.925 | 699.209 | +65.7 % | 305.920.455 |
| UBS Group AG | 1.114.451 | 450.161 | +67.8 % | 193.390.683 |
| MORGAN STANLEY | 2.693.568 | 406.658 | +17.8 % | 467.415.402 |
| CITADEL ADVISORS LLC | 504.936 | 277.122 | +121.6 % | 87.621.544 |
| JANE STREET GROUP, LLC | 402.034 | 237.077 | +143.7 % | 69.764.960 |
| DAVIS SELECTED ADVISERS | 1.589.883 | 228.271 | +16.8 % | 275.895.498 |
| Woodline Partners LP | 341.372 | 223.936 | +190.7 % | 59.238.283 |
| Qube Research & Technologies Ltd | 733.456 | 203.656 | +38.4 % | 127.276.620 |
| ACADIAN ASSET MANAGEMENT LLC | 190.975 | 188.181 | +6735.2 % | 33.129 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| WELLINGTON MANAGEMENT GROUP LLP | 100.146 | -1.341.737 | -93.1 % | 17.378.335 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 6.297.157 | -708.833 | -10.1 % | 1.092.746 |
| BlackRock, Inc. | 9.459.218 | -542.817 | -5.4 % | 1.641.458.028 |
| Neuberger Berman Group LLC | 43.821 | -474.675 | -91.5 % | 7.604.344 |
| MARSHALL WACE, LLP | 93.217 | -463.938 | -83.3 % | 16.175.946 |
| MACQUARIE GROUP LTD | 15.687 | -255.634 | -94.2 % | 2.718.442 |
| ROYAL BANK OF CANADA | 228.731 | -243.498 | -51.6 % | 39.691.000 |
| BALYASNY ASSET MANAGEMENT L.P. | 1.695 | -219.808 | -99.2 % | 294.133 |
| VICTORY CAPITAL MANAGEMENT INC | 2.126.422 | -217.552 | -9.3 % | 368.998.036 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 299.628 | -193.404 | -39.2 % | 51.994.447 |
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Zweck |
|---|---|---|---|---|---|---|
| 30.04.2026 | Vanguard Capital Management | Passiv (13G) | 7,53 % | 8.274.567 | Neu | |
| 29.04.2026 | Vanguard Portfolio Management | Passiv (13G) | 5,54 % | 6.096.629 | Neu | |
| 27.03.2026 | The Vanguard Group | Passiv (13G/A) | Ausstieg | 0 | -12,07 pp | |
| 14.08.2025 | T. Rowe Price Associates, Inc. | Passiv (13G/A) | 6,50 % | 7.209.622 | +1,10 pp | |
| 14.05.2025 | T. Rowe Price Associates, Inc. | Passiv (13G) | 5,40 % | 5.995.335 | Neu | |
| 17.04.2025 | BlackRock, Inc. | Passiv (13G/A) | 8,40 % | 9.308.815 | Neu | |
| 13.02.2024 | The Vanguard Group | Passiv (13G/A) | 12,07 % | 13.575.974 | -0,20 pp | |
| 25.01.2024 | : STATE STREET CORPORATION | Passiv (13G/A) | 4,76 % | 0 | -0,40 pp | |
| 24.01.2024 | . BlackRock, Inc. | Passiv (13G/A) | 9,40 % | 10.578.025 | -1,50 pp | |
| 09.02.2023 | The Vanguard Group | Passiv (13G/A) | 12,27 % | 13.973.339 | +1,36 pp | |
| 07.02.2023 | : STATE STREET CORPORATION | Passiv (13G/A) | 5,16 % | 0 | +0,05 pp | |
| 23.01.2023 | . BlackRock, Inc. | Passiv (13G/A) | 10,90 % | 12.391.327 | +0,20 pp | |
| 08.04.2022 | . BlackRock, Inc. | Passiv (13G/A) | 10,70 % | 12.807.624 | +1,20 pp | |
| 10.02.2022 | The Vanguard Group | Passiv (13G/A) | 10,91 % | 13.377.729 | +0,27 pp | |
| 10.02.2022 | : STATE STREET CORPORATION | Passiv (13G) | 5,11 % | 0 | Neu | |
| 07.02.2022 | . BlackRock, Inc. | Passiv (13G/A) | 9,50 % | 11.636.382 | +1,00 pp |
US Congress Trades (STOCK Act)
| Datum | Mitglied | Partei | Kammer | Typ | Betrag-Bereich |
|---|---|---|---|---|---|
| 03.11.2025 | Julie Johnson | – | House | Verkauf | $1,001 – $15,000 |
| 24.07.2025 | Julia Letlow | – | House | Verkauf | $1,001 – $15,000 |
| 28.04.2025 | Julia Letlow | – | House | Kauf | $1,001 – $15,000 |
| 10.03.2025 | Carol Devine Miller | – | House | Verkauf | $1,001 – $15,000 |
Quelle: House eFD & Senate eFD (STOCK Act PTR). Betragsangaben sind Bereichsangaben — keine Exaktwerte. Tiefenanalyse für diese Aktie → · Alle Kongress-Bestände →
Stammdaten
Quest Diagnostics Incorporated bietet Diagnoseclusterverfahren, Informationen und Dienstleistungen in den Vereinigten Staaten und international. Das Unternehmen entwickelt und erbringt Diagnoseinformationsdienstleistungen wie Routineuntersuchungen, nicht-routinemäßige und fortgeschrittene klinische Untersuchungen, anatomische Pathologieuntersuchungen und weitere Diagnoseinformationsdienstleistungen. Es bietet Diagnoseinformationsdienstleistungen primär unter der Marke Quest Diagnostics sowie unter den Marken AmeriPath, Dermpath Diagnostics, ExamOne und Quanum für Patienten, Kliniker, Krankenhäuser, unabhängige Liefernetze, Krankenversicherungen, Arbeitgeber, direkte Vertragskunden und verantwortungsvolle Pflegeorganisationen über ein Netz von Laboratorien, Patientenservice-Zentren, Phlebotomisten in Arztpraxen, Call-Center und mobile Rettungsteams, Pflegekräfte und weitere Gesundheits- und Wellness-Fachkräfte. Das Unternehmen bietet auch Risikobewertungsdienstleistungen für die Lebensversicherungsindustrie; sowie robusten Informationstechnologie-Lösungen für Gesundheitsorganisationen und Kliniker. Quest Diagnostics Incorporated wurde 1967 gegründet und hat seinen Sitz in Secaucus, New Jersey.
Unternehmen & Branche
| Name | QUEST DIAGNOSTICS INC |
|---|---|
| Ticker | DGX |
| CIK | 0001022079 |
| Boerse | NYSE |
| Sektor | Healthcare |
| Industrie | Medical - Diagnostics & Research |
| SIC | 8071 · Services-Medical Laboratories |
Wertpapier & Kennzahlen
| CUSIP | 74834l100 |
|---|---|
| ISIN | US74834L1008 |
| Typ | Common Stock |
| Marktkapitalisierung | 23,03 Mrd. USD |
| KGV (P/E) | 23,29 |
| Beta | 0,60 |
| Dividendenrendite | 0,01 % |
Bewertung
| KBV (P/B) | 3,21 vs. 3,44 (2021) ▼ |
|---|---|
| KUV (P/S) | 2,09 vs. 2,05 (2021) ▲ |
| EV/EBITDA | 13,6 vs. 9,3 (2021) ▲ |
| FCF-Rendite | 5,9 % vs. 8,3 % (2021) ▼ |
| Buyback-Rendite | 2,0 % vs. 9,9 % (2021) ▼ |
| Ausschüttungsquote | 35,6 % vs. 15,5 % (2021) ▲ |
Qualität & Bilanz
| Bruttomarge | 33,2 % vs. 39,0 % (2021) ▼ |
|---|---|
| Operative Marge | 14,1 % vs. 22,1 % (2021) ▼ |
| Nettomarge | 9,0 % vs. 18,5 % (2021) ▼ |
| ROIC | 7,3 % vs. 17,9 % (2021) ▼ |
| Nettoverschuldung/EBITDA | 2,8 vs. 1,4 (2021) ▲ |
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | Verlauf |
|---|---|---|---|---|---|---|
| Bewertung | ||||||
| KBV (P/B) | 3,44 | 3,13 | 2,47 | 2,52 | 2,73 | |
| KUV (P/S) | 2,05 | 1,87 | 1,68 | 1,73 | 1,78 | |
| EV/EBITDA | 9,3 | 12,2 | 11,9 | 12,7 | 12,0 | |
| FCF-Rendite | 8,3 % | 7,1 % | 5,5 % | 5,3 % | 6,9 % | |
| Buyback-Rendite | 9,9 % | 7,6 % | 1,8 % | 0,9 % | 2,3 % | |
| Ausschüttungsquote | 15,5 % | 32,2 % | 36,8 % | 38,0 % | 35,6 % | |
| Qualität & Bilanz | ||||||
| Bruttomarge | 39,0 % | 34,7 % | 33,0 % | 32,9 % | 33,2 % | |
| Operative Marge | 22,1 % | 14,4 % | 13,6 % | 13,6 % | 14,1 % | |
| Nettomarge | 18,5 % | 9,6 % | 9,2 % | 8,8 % | 9,0 % | |
| ROIC | 17,9 % | 9,0 % | 7,3 % | 6,3 % | 7,3 % | |
| Nettoverschuldung/EBITDA | 1,4 | 2,3 | 2,8 | 3,5 | 2,8 | |
| Zinsdeckungsgrad | 15,7 | 9,6 | 7,7 | – | – | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Finanzkennzahlen (SEC XBRL) ⓘ
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | 2.895.000.000 | 252.000.000 | 2,24 | 16.673.000.000 | 7.366.000.000 |
| 2025-12-31 | 10-K | 11.035.000.000 | 992.000.000 | 8,75 | 16.225.000.000 | 7.170.000.000 |
| 2025-09-30 | 10-Q | 2.816.000.000 | 245.000.000 | 2,16 | 16.197.000.000 | 7.258.000.000 |
| 2025-06-30 | 10-Q | 2.761.000.000 | 282.000.000 | 2,47 | 15.969.000.000 | 7.228.000.000 |
| 2025-03-31 | 10-Q | 2.652.000.000 | 220.000.000 | 1,94 | 15.797.000.000 | 6.929.000.000 |
| 2024-12-31 | 10-K | 9.872.000.000 | 871.000.000 | 7,69 | 16.153.000.000 | 6.778.000.000 |
| 2024-09-30 | 10-Q | 2.488.000.000 | 226.000.000 | 1,99 | 16.095.000.000 | 6.809.000.000 |
| 2024-06-30 | 10-Q | 2.397.000.000 | 229.000.000 | 2,03 | 13.881.000.000 | 6.617.000.000 |
| 2024-03-31 | 10-Q | 2.366.000.000 | 194.000.000 | 1,72 | 13.954.000.000 | 6.432.000.000 |
| 2023-12-31 | 10-K | 9.252.000.000 | 854.000.000 | 7,49 | 14.022.000.000 | 6.307.000.000 |
| 2023-09-30 | 10-Q | 2.295.000.000 | 225.000.000 | 1,96 | 13.482.000.000 | 6.425.000.000 |
| 2023-06-30 | 10-Q | 2.338.000.000 | 235.000.000 | 2,05 | 13.425.000.000 | 6.249.000.000 |
| 2023-03-31 | 10-Q | 2.331.000.000 | 202.000.000 | 1,78 | 12.794.000.000 | 6.050.000.000 |
| 2022-12-31 | 10-K | 9.883.000.000 | 946.000.000 | 7,97 | 12.837.000.000 | 5.893.000.000 |
| 2022-09-30 | 10-Q | 2.486.000.000 | 256.000.000 | 2,17 | 13.223.000.000 | 6.235.000.000 |
| 2022-06-30 | 10-Q | 2.453.000.000 | 234.000.000 | 1,96 | 13.312.000.000 | 6.411.000.000 |
| 2022-03-31 | 10-Q | 2.611.000.000 | 355.000.000 | 2,92 | 13.442.000.000 | 6.377.000.000 |
| 2021-12-31 | 10-K | 10.788.000.000 | 1.995.000.000 | 15,55 | 13.611.000.000 | 6.444.000.000 |
| 2021-09-30 | 10-Q | 2.774.000.000 | 505.000.000 | 4,02 | 13.572.000.000 | 6.392.000.000 |
| 2021-06-30 | 10-Q | 2.550.000.000 | 631.000.000 | 4,96 | 12.861.000.000 | 5.899.000.000 |
Umsatz nach Segmenten & Regionen ⓘ
Geschäftssegmente
| Segment | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| Diagnostic Information Services Business | 10,8 Mrd. | 9,6 Mrd. | 9,0 Mrd. | 9,6 Mrd. | – | 97,7 % | +12,2% | |
| All Other Segments | 250,0 Mio. | 258,0 Mio. | 276,0 Mio. | 274,0 Mio. | – | 2,3 % | -3,1% | |
| Routineclinicaltestingservices | – | – | – | – | 4,3 Mrd. | – | – | |
| Genebasedandesoterictestingservices | – | – | – | – | 2,9 Mrd. | – | – | |
| COVID 19 Testing Services | – | – | – | – | 2,8 Mrd. | – | – | |
| Anatomicpathologytestingservices | – | – | – | – | 553,0 Mio. | – | – | |
| Allotherservices | – | – | – | – | 294,0 Mio. | – | – |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 22.04.2026 | 2,9 Mrd. USD | 2,24 |
| Q3 2025 | 30.09.2025 | 22.04.2026 | 2,8 Mrd. USD | 2,16 |
| Q2 2025 | 30.06.2025 | 22.04.2026 | 2,8 Mrd. USD | 2,47 |
| Q1 2025 | 31.03.2025 | 22.04.2026 | 2,7 Mrd. USD | 1,94 |
| Q3 2024 | 30.09.2024 | 21.10.2025 | 2,5 Mrd. USD | 1,99 |
| Q2 2024 | 30.06.2024 | 21.10.2025 | 2,4 Mrd. USD | 2,03 |
| Q1 2024 | 31.03.2024 | 21.10.2025 | 2,4 Mrd. USD | 1,72 |
| Q3 2023 | 30.09.2023 | 23.10.2024 | 2,3 Mrd. USD | 1,96 |
| Q2 2023 | 30.06.2023 | 23.10.2024 | 2,3 Mrd. USD | 2,05 |
Einreichungs-Historie (10-K / 10-Q)
SEC-Einreichungs-Historie der Quartalsberichte (10-Q) und Jahresberichte
(10-K) der letzten sechs Jahre. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 22.04.2026 | 10-Q | – | – | SEC » |
| 26.02.2026 | 10-K | 31.12.2025 | 57 Tage | SEC » |
| 21.10.2025 | 10-Q | 30.09.2025 | 21 Tage | SEC » |
| 23.07.2025 | 10-Q | 30.06.2025 | 23 Tage | SEC » |
| 23.04.2025 | 10-Q | 31.03.2025 | 23 Tage | SEC » |
| 20.02.2025 | 10-K | 31.12.2024 | 51 Tage | SEC » |
| 23.10.2024 | 10-Q | 30.09.2024 | 23 Tage | SEC » |
| 24.07.2024 | 10-Q | 30.06.2024 | 24 Tage | SEC » |
| 24.04.2024 | 10-Q | 31.03.2024 | 24 Tage | SEC » |
| 22.02.2024 | 10-K | 31.12.2023 | 53 Tage | SEC » |
| 25.10.2023 | 10-Q | 30.09.2023 | 25 Tage | SEC » |
| 27.07.2023 | 10-Q | 30.06.2023 | 27 Tage | SEC » |
| 28.04.2023 | 10-Q | 31.03.2023 | 28 Tage | SEC » |
| 21.02.2023 | 10-K | 31.12.2022 | 52 Tage | SEC » |
| 21.10.2022 | 10-Q | 30.09.2022 | 21 Tage | SEC » |
| 22.07.2022 | 10-Q | 30.06.2022 | 22 Tage | SEC » |
| 22.04.2022 | 10-Q | 31.03.2022 | 22 Tage | SEC » |
| 28.02.2022 | 10-K | 31.12.2021 | 59 Tage | SEC » |
| 22.10.2021 | 10-Q | 30.09.2021 | 22 Tage | SEC » |
| 23.07.2021 | 10-Q | 30.06.2021 | 23 Tage | SEC » |
| 23.04.2021 | 10-Q | 31.03.2021 | 23 Tage | SEC » |
| 22.02.2021 | 10-K | 31.12.2020 | 53 Tage | SEC » |
| 23.10.2020 | 10-Q | 30.09.2020 | 23 Tage | SEC » |
| 24.07.2020 | 10-Q | 30.06.2020 | 24 Tage | SEC » |
Kritische 8-K Meldungen ⓘ
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 21.05.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Section 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors… |
| 29.09.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors… |
| 18.11.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 01.11.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 28.10.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 01.07.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 14.06.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 25.05.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 02.03.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 01.03.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 01.03.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 03.02.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 19.08.2021 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 17.08.2021 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 23.02.2021 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 23.02.2021 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 24.06.2020 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 16.03.2020 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |